Core Insights - Predictive Oncology Inc. has appointed Shawn Matthews, Thomas McLaughlin, and Sara Turken to its leadership team and Board of Directors to support its new digital asset treasury strategy focused on the Aethir (ATH) token [1][2][3] Leadership Appointments - Shawn Matthews, CEO of DNA Holdings Venture, Inc. and former CEO of Cantor Fitzgerald, joins the Board of Directors [2][3] - Thomas McLaughlin, CIO of DNA Holdings Venture, Inc., is appointed as Chief Investment Officer [2][4] - Sara Turken, JD, a biopharmaceutical veteran, is appointed as General Counsel [2][5] Strategic Focus - The company is leveraging its AI-driven drug discovery capabilities to implement an innovative digital treasury asset strategy, which aims to address its AI requirements and capitalize on the growing global need for AI infrastructure [3][8] - Predictive Oncology operates a digital asset treasury focused on the Aethir (ATH) token, creating the world's first Strategic Compute Reserve [8] Company Background - Predictive Oncology utilizes AI and machine learning to expedite early drug discovery, with its platform, PEDAL, achieving 92% accuracy in predicting tumor responses to drug compounds [6][7] - The company has a biobank of over 150,000 assay-capable heterogeneous human tumor samples, providing extensive AI-based drug discovery solutions [7]

Market Overview - The global neurology devices market is projected to reach a valuation of USD 11,678 million in 2025, with an expected CAGR of 6.7% from 2025 to 2035 [1][8] - The market created an opportunity of USD 2,245 million growing at a CAGR of 5.9% between 2020 to 2025 [8] Neurological Disease Burden - Over 1 in 3 adults worldwide are affected by neurological diseases, making it the largest cause of disease and impairment globally [2] - From 1990 to 2021, the overall disability and early death due to neurological diseases rose by 18%, with 3.4 million people (43.1%) living with such conditions in 2021 [3] Technological Advancements - Continuous growth in neurology devices is attributed to the development of minimally invasive devices utilizing artificial intelligence for superior diagnosis and treatment [4] - Companies are innovating and forming strategic partnerships to enhance market dominance in response to the rising demand for improved neurological treatments [9] Market Drivers - The increasing prevalence of neurological disorders, such as Alzheimer's and Parkinson's diseases, is driving demand for treatment devices and diagnostic equipment [5] - The aging population is more vulnerable to neurological disorders, further increasing the demand for advanced neurology devices [5] Healthcare Spending and Accessibility - Rising healthcare spending in emerging economies is improving patient access to advanced neurology devices, supported by government initiatives and favorable reimbursement policies [6] Key Players and Innovations - Leading companies in the neurology devices market include Medtronic, Boston Scientific Corporation, Stryker Corporation, and Abbott Laboratories [9][17] - Significant investments in research and development are being made, such as Precision Neuroscience's funding of USD 102 million for brain-computer interface technology [11] Clinical Trials and New Technologies - A partnership between Amber Therapeutics and Oxford University conducted a clinical trial of Picostim, demonstrating an 80% reduction in seizures for neurological disorder treatment [12] - Inbrain Neuroelectronics introduced a brain implant made from graphene, aimed at improving outcomes in brain cancer surgeries and treating conditions like Parkinson's disease and epilepsy [13] Market Segmentation - The study categorizes the market based on device type, application (e.g., Alzheimer's, Parkinson's), and end user (e.g., hospitals, neurology clinics) across major global regions [15]

As filed with the Securities and Exchange Commission on January 12, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 2836 94-3078125 (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identification Number) 288 Grove Street, ...

As filed with the Securities and Exchange Commission on February 7, 2023 Registration No. 333-269475 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SINTX Technologies, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 3841 84-1375299 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identificatio ...